Bdsi

JUN 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Belbuca (REMS)

U.S. Food and Drug Administration

This is an FDA supplemental approval action for a Risk Evaluation and Mitigation Strategy (REMS) modification to an existing buprenorphine product; it does not report clinical trial data or comparative efficacy.